Ciprofloxacin inhalation - Aradigm

Drug Profile

Ciprofloxacin inhalation - Aradigm

Alternative Names: ARD-1100; ARD-3100; ARD-3150; CFI; Ciprofloxacin AERx formulation - Aradigm; Ciprofloxacin inhalation modified-release - Aradigm Corporation; Ciprofloxacin inhalation sustained-release - Aradigm; Ciprofloxacin liposomal sustained-release - Aradigm; DRCFI; Dual Release Ciprofloxacin for Inhalation; ILCH; Inhaled liposomal ciprofloxacin hydrochloride; Lipoquin; Pulmaquin

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Aradigm Corporation
  • Developer Aradigm Corporation; Oregon State University
  • Class Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA topoisomerase IV inhibitors; Type II bacterial DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchiectasis; Cystic fibrosis-associated respiratory tract infections
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Bronchiectasis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Bronchiectasis
  • Preclinical Acinetobacter infections; Anthrax; Mycobacterial infections; Pneumonic plague; Q fever; Tularaemia; Yersinia infections
  • Suspended Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 01 Dec 2016 Top-line efficacy and safety data from two phase III trials (ORBIT-3 and ORBIT-4) in non-cystic fibrosis Bronchiectasis released by Aradigm Corporation
  • 09 Nov 2016 Updated adverse events data from the ORBIT-1 IIb trial in Bronchiectasis released by Aradigm Corporation
  • 01 Oct 2016 Aradigm Corporation completes the ORBIT-3 trials in Bronchiectasis in US, Australia, Canada, Hungary, Ireland, Israel, Italy, South Korea, South Africa, Latvia, Poland, Romania, Spain, Taiwan and United Kingdom (NCT01515007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top